Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec '23 Dec 31, 2023
Novel Synthetic Lethality-based Cancer Therapeutics	583.23K

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec '23 Dec 31, 2023
Sweden	583.23K